Post Menopausal Osteoporosis Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

 Market Overview:

The post menopausal osteoporosis market reached a value of USD 3.6 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2025. Looking forward, IMARC Group expects the top 7 major markets to reach USD 5.3 Billion by 2036, exhibiting a growth rate (CAGR) of 3.51% during 2026-2036.

The post menopausal osteoporosis market has been comprehensively analyzed in IMARC's new report titled "Post Menopausal Osteoporosis Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036". Post menopausal osteoporosis is a type of osteoporosis that develops in women after menopause. Osteoporosis is a condition characterized by low bone density and structural deterioration of bone tissue, leading to increased fragility as well as a higher risk of fractures. Post menopausal osteoporosis often does not cause noticeable symptoms until a fracture occurs. However, some common indications may be present, including back pain, loss of height over time, a stooped posture (kyphosis), greater susceptibility to fractures, particularly in the wrist, hip, and spine, etc. In many cases, fractures can occur with minimal trauma or even during routine daily activities. The diagnosis of post menopausal osteoporosis typically involves a combination of clinical assessment and diagnostic tests. Healthcare professionals evaluate the patient's medical history, risk factors, and symptoms to determine the likelihood of osteoporosis. Dual-energy X-ray absorptiometry (DXA) is the most commonly used test to measure bone mineral density (BMD) and diagnose osteoporosis. Numerous additional procedures, such as laboratory blood tests and vertebral imaging, may be done to rule out other causes and assess fracture risk.

The escalating cases of decline in estrogen levels during menopause that result in an imbalance between bone formation and bone resorption, thereby leading to a net loss of bone density, are primarily driving the post menopausal osteoporosis market. Furthermore, the rising incidence of several associated risk factors, including genetic predisposition, inadequate intake of calcium and vitamin D, lack of physical activity, prolonged use of corticosteroids, excessive alcohol consumption, etc., is also bolstering market growth. In addition to this, the widespread adoption of oral bisphosphonates, such as alendronate and risedronate, to inhibit bone resorption and reduce the likelihood of fractures in patients is creating a positive outlook for the market. Moreover, the rising utilization of novel sequential therapies involving the use of anabolic agents like teriparatide followed by antiresorptive medications for optimizing bone formation and reducing bone loss is acting as another significant growth-inducing factor. Additionally, the emerging popularity of the trabecular bone score (TBS) imaging technique, since it assesses the microarchitecture of trabecular bone and provides additional information about bone quality, fracture risk, and treatment response, is expected to drive the post menopausal osteoporosis market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the post menopausal osteoporosis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for post menopausal osteoporosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the post menopausal osteoporosis market in any manner.

Recent Developments:

• In February 2025, Samsung Bioepis disclosed that the FDA had approved Ospomyv (denosumab-dssb; SB16) and Xbryk (denosumab-dssb; SB16), biosimilars referencing Amgen’s Prolia and Xgeva, respectively. Ospomyv is indicated for osteoporosis treatment in postmenopausal women and men at high risk of fracture, as well as for patients undergoing androgen deprivation or aromatase inhibitor therapy.
• In December 2024, Gedeon Richter and Hikma Pharmaceuticals announced that the U.S. FDA had accepted for review the Biologics License Applications (BLA) for RGB-14, a Denosumab biosimilar candidate comprising two biosimilar products referencing Prolia and Xgeva, a human monoclonal antibody for the treatment of osteoporosis and fractures due to bone metastasis.
• In October 2024, Teva Pharmaceutical Industries Ltd. stated that the U.S. FDA had accepted, and the European Medicines Agency (EMA) had validated, applications for TVB-009P, a biosimilar candidate to Prolia (denosumab).
• In May 2024, Fresenius Kabi announced that the U.S. FDA had accepted for review the company’s Biologics License Application (BLA) for FKS518, its biosimilar candidate of Prolia (denosumab) and Xgeva (denosumab) to treat post-menopausal osteoporosis.

Key Highlights:

• The prevalence of osteoporosis in post menopausal women rises with age, affecting 10.96% of women aged 60 to 69 and 26.48% of those over 70.
• The WHO estimates that 30% of post menopausal women have osteoporosis.
• Osteopenia prevalence increases with age in post menopausal women.
• According to WHO criteria, 30% of Caucasian post menopausal women in the United States have osteoporosis, whereas 54% have osteopenia.

Drugs:

Evenity (romosozumab) is a bone-building medication for postmenopausal women with osteoporosis who are at high risk of fracture. It's an antibody that blocks sclerostin, a chemical that prevents bone development. Evenity can help lower the risk of spine fractures and build up new bone in 12 months.

RGB-14, also known as denosumab, is a fully human monoclonal antibody that treats postmenopausal osteoporosis by inhibiting bone resorption. It works by binding to RANKL (Receptor activator of nuclear factor kappa-B ligand), preventing it from interacting with its receptor (RANK) on osteoclast precursor cells. This interaction is crucial for osteoclast formation, activity, and survival, thus inhibiting bone breakdown.

TVB-009P is a monoclonal antibody and a biosimilar candidate to Prolia (denosumab). It works by targeting RANKL, a key protein involved in bone remodeling. It inhibits RANKL, which in turn blocks the formation, activity, and survival of osteoclasts, the cells responsible for breaking down bone. This mechanism reduces bone resorption, increases bone mineral density, and ultimately reduces the risk of fractures in postmenopausal women with osteoporosis.

Time Period of the Study

• Base Year: 2025
• Historical Period: 2020-2025
• Market Forecast: 2026-2036

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the post menopausal osteoporosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the post menopausal osteoporosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current post menopausal osteoporosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the post menopausal osteoporosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
• What was the country-wise size of the post menopausal osteoporosis across the seven major markets in 2025 and what will it look like in 2036?
• What is the growth rate of the post menopausal osteoporosis across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2020-2036) of post menopausal osteoporosis across the seven major markets?
• What is the number of prevalent cases (2020-2036) of post menopausal osteoporosis by age across the seven major markets?
• What is the number of prevalent cases (2020-2036) of post menopausal osteoporosis by gender across the seven major markets?
• What is the number of prevalent cases (2020-2036) of post menopausal osteoporosis by type across the seven major markets?
• How many patients are diagnosed (2020-2036) with post menopausal osteoporosis across the seven major markets?
• What is the size of the post menopausal osteoporosis patient pool (2020-2025) across the seven major markets?
• What would be the forecasted patient pool (2026-2036) across the seven major markets?
• What are the key factors driving the epidemiological trend post menopausal osteoporosis of?
• What will be the growth rate of patients across the seven major markets?

Post Menopausal Osteoporosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for post menopausal osteoporosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the post menopausal osteoporosis market?
• What are the key regulatory events related to the post menopausal osteoporosis market?
• What is the structure of clinical trial landscape by status related to the post menopausal osteoporosis market?
• What is the structure of clinical trial landscape by phase related to the post menopausal osteoporosis market?
• What is the structure of clinical trial landscape by route of administration related to the post menopausal osteoporosis market?